

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 12th February, 2021

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and nine months ended on 31st December, 2020 and Limited Review Report on Un-audited Financial Results for the quarter and nine months ended on 31st December, 2020.

You are requested to kindly take the same on record.

Thanking You,
Yours Faithfully

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD


Company Secretary

**AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: 29371**

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2020

Rs.in Lakhs

S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	(Audited)
I.	Revenue from Operations	46.26	1,038.14	141.86	1,084.40	351.42	540.03
II.	Other Income	1.65	2.06	1.98	5.72	6.04	8.02
III.	Total Income (I+II)	47.91	1,040.20	143.84	1,090.12	357.46	548.05
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	46.22	1,000.30	130.30	1,046.52	338.30	512.69
	Changes in inventories of:						
	Finished Goods	-	-	-	-	-	-
	Work in Progress	-	-	-	-	-	-
	Stock in Trade	-	-	-	-	-	-
	Employee Benefit Expenses	2.99	2.62	2.44	8.45	8.83	9.06
	Finance Cost	-	0.01	-	0.01	0.03	0.21
	Depreciation and Amortisation Expenses	0.08	0.08	-	0.24	0.25	0.33
	Other expenses	1.56	20.11	1.50	24.86	6.44	8.72
	Total Expenses (IV)	50.85	1,023.12	134.24	1,080.08	353.85	531.01
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(2.94)	17.08	9.60	10.04	3.61	17.04
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Tax (V-VI)	(2.94)	17.08	9.60	10.04	3.61	17.04
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	2.66
	(2) Deferred Tax	-	-	-	-	-	11.09
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(2.94)	17.08	9.60	10.04	3.61	3.29
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	(2.94)	17.08	9.60	10.04	3.61	3.29
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(2.94)	17.08	9.60	10.04	3.61	3.29
XVI.	Earnings per Equity Share						
	(1) Basic	(0.17)	0.99	0.56	0.58	0.21	0.19
	(2) Diluted	(0.17)	0.99	0.56	0.58	0.21	0.19
XVII.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59

Notes:

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 12th February 2021.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 31-Dec-2020 nor any pending as on 01-Jan-2021.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.



For and on behalf of the Board
Sarda Proteins Ltd
For Sarda Proteins Limited

Director

Place: Jaipur
Date: 12-Feb-2021

Deepak Data (DIN: 01672415)
Managing Director



Khetawat Agarwal & Co.
Chartered Accountants

Limited Review Report
Unaudited Standalone Quarterly and Nine Months Results


To
The Board of Directors
Sarda Proteins Ltd


We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Nine Months ended on 31st December, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co.
Chartered Accountants
FRN: 003960C


M.L. Agarwal
Partner
M. No.: 072854



UDIN : 21072854AAAAAF5286

Place : Jaipur
Date : 12.02.2021